FLUDARA

Country: Իսրայել

language: անգլերեն

source: Ministry of Health

active_ingredient:

FLUDARABINE PHOSPHATE 50 MG/VIAL

MAH:

SANOFI - AVENTIS ISRAEL LTD

ATC_code:

L01BB05

pharmaceutical_form:

POWDER FOR SOLUTION FOR INJ/INF

administration_route:

I.V

manufactured_by:

GENZYME EUROPE B.V., NETHERLANDS

therapeutic_group:

FLUDARABINE

therapeutic_indication:

Palliative treatment of patients with CLL refractory to other therapy. Treatment of less malignant Non-Hodgkin lymphoma of stage 3 to 4 in patients who have not responded to standard therapy with at least one alkylating agent or in whom the disease progressed during or after standard therapy. Fludara is indicated for the initial treatment of patients with B- cell chronic lymphocytic leukaemia (CLL) or after first line therapy, in patients with sufficient bone marrow reserves.

authorization_date:

2009-02-01